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Abstract
The distinction between metastasis from a colorectal adenocarcinoma into the ovary and an
ovarian adenocarcinoma is vital, but challenging at times, due to overlapping morphological
features. Similarly, a distinction between an ovarian metastasis into the colorectum and a colorectal
adenocarcinoma, although rare; is important and can be daunting. We report an analysis of 20 cases
of ovarian involvement by metastatic colorectal adenocarcinomas and colorectal involvement by
metastatic ovarian adenocarcinomas, including the value of differential expression of cytokeratins
7 & 20 by immunohistochemistry (IHC), in these cases. Nine cases (45%) were identified as
colorectal adenocarcinomas metastatic to the ovary. On biopsy, all these cases showed a 'garland-
like' tumor necrosis, with desmoplasia and predominantly exhibited a tubuloalveolar pattern (67%
cases). On IHC, all 8 of 9 such cases, where staining for cytokeratin 20 was performed, displayed
strong positivity and 7 cases, where staining for carcinoembryogenic antigen (CEA) was performed,
revealed positivity for this marker (100%). Other 11 cases (55%) were ovarian adenocarcinomas,
metastatic to the colorectum. These showed metachronous presentations, with the ovarian tumor
preceding the colorectal tumor deposits. Morphologically, psammomatous calcification was noted
in 73% of these cases, whereas 'garland-like' necrosis was absent in all. The chief morphological
subtype was serous papillary cystadenocarcinoma (55% cases). On IHC, CK7 and CA 125 were
positive in all 6 of 11 such cases, whereas CK 20 was negative in all these cases.
In cases of complex presentations like an ovarian involvement by a metastatic colorectal
adenocarcinoma and vice-versa, certain clinicopathological features are useful. Differential
expression of CK 7 and CK20 is vital in resolving these dilemmas. CK20 positivity and CK7
negativity is associated with a colorectal adenocarcinoma. Markers like CEA and CA-125 have an
added value.
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The ovary is a site for a wide range of tumors, both pri-
mary and metastatic. Approximately 10–30% of ovarian
tumors are metastatic, commonly from the breast, stom-
ach, and the colon [1]. Of these, colorectal metastasis
account for approximately 4% [2]. Morphologically, these
tumors mimic primary ovarian adenocarcinomas, espe-
cially ovarian endometrioid adenocarcinomas. Rarely,
colorectum becomes a site for a metastasis from an ovar-
ian adenocarcinoma [3]. Identification of the correct pri-
mary tumor in both the described presentations is
necessary for an optimal management, including, specific
chemotherapy (CT) in advanced stages. Whereas, ovarian
adenocarcinomas respond to platinum based CT, cases of
colonic adenocarcinomas are candidates for 5-fluorouro-
cil based CT. [4]. The known clinical features favoring a
metastatic tumor into the ovary include history of an ante-
cedent malignancy, relatively smaller size of the tumor
~10 cms, solid structure, frequent bilaterality; absence of
ascites and elevated serum carcinoembryonic antigen
(CEA) levels [1]. Certain morphological features indica-
tive of metastasis from colorectum include 'garland-like'
tumor necrosis, segmental destruction of glands and
absence of squamous metaplasia, whereas cribriform
growth patterns and intraluminal "dirty" necrosis are
indicators of endometrioid ovarian adenocarcinomas
[5,6]. However, problem exists in sorting out these
tumors, including in cases mucinous adenocarcinomas,
when there is simultaneous involvement of the ovary and
the colorectum at similar (synchronous) or at different
(metachronous) times [6,7]. Lately, cytokeratins 7 and 20
have emerged to resolve these diagnostic dilemmas [7-9].
We sought to evaluate distinct clinicopathological fea-
tures, along with value of differential expression of CK7
and CK20 in certain cases of ovarian involvement by met-
astatic colorectal adenocarcinomas, as well as in uncom-
mon cases of colorectal involvement by metastatic
ovarian adenocarcinomas.
Methods
Twenty cases of ovarian tumors, including colorectal ade-
nocarcinomas metastatic to the ovary and ovarian adeno-
carcinomas metastatic to the colorectum, were retrieved
from the surgical pathology records, over a period of 5
years at a tertiary cancer referral centre. These included 'in-
house' specimens as well as paraffin blocks and slides for
review. Histologic confirmation of either ovarian or color-
ectal involvement was present, with radiological confir-
mation of the metastatic deposits. Cases of metastatic
adenocarcinomas to the ovary from other sites were
excluded.
Clinical details were retrieved from the charts and depart-
mental electronic medical records (EMR). These included
parameters like age, anatomic site of primary malignancy,
radiological details with serum tumor marker levels, stage
of the disease; disease status like synchronous or meta-
chronous involvement and additional metastasis, if any.
Wherever available, gross features of the ovaries were tab-
ulated including laterality, presence of capsular breach,
surface component and presence of solid or cystic areas on
cut sections. Haematoxylin and eosin sections (H&E)
were available in all cases. Mucicarmine stain was
employed in cases of mucinous or 'signet-ring' cell
tumors.
Histomorphologically, the tumors were evaluated for
type, degree of differentiation, presence of normal ovarian
parenchyma, presence of 'garland-like' necrosis, defined
as cystic glandular structures containing necrotic debris
encircled by an array of round tubular glands [3]; lym-
phovascular emboli (LVI), stromal luteinization, desmo-
plastic response, squamoid differentiation, and
psammomatous calcification.
Sections from the colorectal tumor were studied for tumor
type, degree of differentiation and stage, including loca-
tion of tumor i.e. whether mucosal or serosal, & invasion
of the muscularis propria.
Immunohistochemistry (IHC) was performed on forma-
lin fixed, paraffin embedded tissue sections by immu-
noperoxidase technique using the avidin-biotin method.
The various antibody markers along with their respective
dilutions, code and antigen retrieval method included
cytokeratin (CK) 7 (1:100, OV-TL-12/30, DAKO, mono-
clonal, code M 7018; by microwave heating), CK 20 (1:50,
Ks 20.8, DAKO, monoclonal, code M 7019), carcinoem-
bryogenic antigen (CEA) (1:600, DAKO, polyclonal; by
enzymatic i.e. pepsin digestion) and CA-125 (1:50, OC
125, DAKO, monoclonal, code M 3519; by microwave
heating). The location of staining was graded as luminal,
membranous or cytoplasmic. The intensity of staining was
graded on a scale on 0–4 as: -Negative-<5%, positive->5%
tumor cells positive. Semiquantitative scoring was as: 0 –
< 5%, 1+ – 6%–25%, 2+ – 26%–50%, 3+ – 51%–75%, 4+
– 76%–100%. Focal staining was interpreted as positivity
in ≤ 50% tumor cells and diffuse staining was interpreted
as positivity in > 50%. [7]. Appropriate controls were
included.
Results
Out of 20 cases, 9 (45%) were of colorectal adenocarcino-
mas, metastatic to the ovary and 11 (55%) cases were of
ovarian adenocarcinomas, metastatic to the colorectum.Page 2 of 7
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Among these cases, median age of presentation was 55
years. The presentation was synchronous in 6/9 (66.6%)
cases. In view of most of these cases being referrals with
limited details, the duration between the two lesions in
cases with metachronous involvement could not be
procured.
Out of 6 cases with available details on laterality, 4
(66.7%) were unilateral and 2 were bilateral (33.3%). On
radiological and gross examination, both, solid and cystic
pattern was the commonest, noted in 4/5 (80%) cases.
Further, capsular breach was noted in all 3 specimens
available for gross examination. The primary tumor was
located in the sigmoid colorectum in 5 (83.3%) cases and
in the ileocaecal region in 1 (16.6%) case. Colonic resec-
tion specimens were available in 2 cases; of which 1 was
of stage T3 N0 Mx and the other was T4 N2 Mx at the time
of diagnosis.
CEA levels were elevated preoperatively in 4 (90%) of 5
cases, where these were available.
Microscopic findings
Morphologically, tubuloglandular/endometrioid mor-
phology was seen in 6 cases; 2 cases were of mucinous
type, while one had 'signet-ring' cell morphology. 'Gar-
land-like' necrosis and desmoplasia was noted in all 9
(100%) cases. Luteinization of the stroma and squamoid
differentiation was not noted in any case. Lymphovascu-
lar emboli (LVI) were present in 5 (55.5%) cases. Psam-
momatous calcification was seen in 1 case.
The colonic resection or biopsy, received in 4 cases,
showed mucosal dysplasia, confirming colonic origin of
the primary.
IHC was performed in 8 cases. All these cases displayed
diffuse (4+) positivity for CK 20. CK7 expression was neg-
ative in 5 and focally positive (1+) in 3 cases. In addition,
variable CEA positivity was observed in 7 cases, where it
was performed. CA-125, performed in 4 cases, was nega-
tive. (Additional file 1) (Figures 1, 2, 3 &4A)
II) Cases of ovarian adenocarcinomas metastatic to 
thecolorectum
Among these, the median age of presentation was 49
years. 81.8% cases were metachronous, with the ovarian
primary preceding the colorectal involvement, while in
one case the patient presented with the tumor of sigmoid
colonic before the ovarian tumor was detected. The
median duration between the colorectal and ovarian
involvement was 3 years. Two cases had synchronous
involvement of the ovaries with the colon.
Seven of 8 cases had bilateral ovarian involvement, with
capsular breach in 5 of 6 cases, where gross details were
available. Status of exact tumor location could be pro-
cured in 7 cases. Of these, the tumor was identified in the
sigmoid colon and rectum in 4 (57.1%) cases, and in the
proximal colon in 3 (42.8%) cases.
Microscopic findings
Morphologically, 6 cases were of serous papillary type, 2
of endometrioid type and remaining 3 cases were of
poorly differentiated adenocarcinoma not otherwise spec-
ified (NOS).
Lymphovascular emboli were noted in 3/11 (27.2%)
cases. Squamoid differentiation, stromal luteinization
was absent, while psammomatous calcification was noted
in 7/11 (63.6%) cases. Desmoplasia was noted in 1 case.
The tumor in the colorectum was predominantly submu-
cosal, in the serosa or in the wall, without mucosal dyspla-
sia in the 9 cases, including colonic resections or biopsies.
IHC was performed in 6 (54.5%) out of 11 cases. CK7 was
diffusely positive in all 6(100%) cases, while CK 20 was
negative in all cases. CA-125, performed in 3 cases, was
positive (100%). CEA, performed in 2 cases, was negative.
(Additional file 1). (Figures 4B, C, D &5).
A. Case of a metastatic colorectal adenocarcinoma to ovary, comprising areas of necr sis (N) surrounded by tum r cells.F cal p ammomatous alcification (a row)igure 1
A. Case of a metastatic colorectal adenocarcinoma 
to ovary, comprising areas of necrosis (N) sur-
rounded by tumor cells. Focal psammomatous calci-
fication (arrow). H&E × 100. B. Higher magnification 
showing tumor cells displaying acinar arrangements with 
psammomatous calcification (arrows). H&E × 100. C. Diffuse 
CK 20 positivity. DAB × 400. D. Diffuse CEA expression. 
DAB × 200.Page 3 of 7
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The histomorphological features of ovarian and colorectal
adenocarcinomas overlap, at times. In certain situations,
the ovarian metastasis form a colorectal adenocarcinoma
might be the primary presentation or a colorectal tumor
might actually be a metastatic adenocarcinoma from the
ovary [3,6]. Identification of an exact primary tumor type
i.e. either ovarian or colorectal, in this scenario becomes
vital for an appropriate management. Apart from certain
clinicopathological features, lately, differential expression
of cytokeratins 7 & 20 has been found to be useful in
resolving these dilemmas [9-11]. The present study was
based on clinicopathological features and identification
of value of differential expression of CK 7 and 20 by
immunohistochemistry, in cases of ovarian involvement
by colorectal adenocarcinomas and. in cases of colorectal
involvement by ovarian adenocarcinomas.
Among the already described clinical features, primary
ovarian adenocarcinomas are usually know to occur at a
relatively younger age group, as was seen in our study
(median age = 49 years), in contrast to ovarian metastatic
deposits from colorectal adenocarcinomas that were seen
in an older age group (mean age = 55 years), as noted in
an earlier study [1]. In our series, involvement of the ovary
and colon in cases of colorectal metastasis was more com-
monly synchronous, in contrast to the findings of Lewis et
al [11], wherein the ovarian lesions were identified prior
to the colonic primary in 32% cases. This might be due to
the fact that that ours being a referral centre, majority of
the patients present at an advanced stage disease, along
with existing lack of routine gynaecologic or gastrointesti-
nal (GI) screening.
The differences in the pre and perioperative characteristics
of primary and secondary ovarian tumors have been stud-
ied by Antila et al [1], who found that tumors that were
relatively smaller -10 cms sized; solid in nature; present-
ing with ascites; in association with raised serum CEA &
tumor-associated trypsin (TAT-1) inhibitor levels, were
predominantly metastatic. Metastatic tumors are reported
to be commonly bilateral [1,6,11]. However, we observed
66% of metastatic colorectal adenocarcinomas in the ova-
ries as unilateral masses, in as noted by Daya et al [12]. In
their study, Lewis et al [11] have also reinforced this fact,
with a suggestion of consideration of metastatic tumor in
cases of younger patients with large sized tumors. Wher-
ever the gross findings were available in our study, all such
cases had a capsular breach and were both solid and cystic
in maximum cases. The mean ovarian tumor size could
not be ascertained in view of referral cases being submit-
ted with limited details, adding to the diagnostic chal-
lenge. In addition, 90% of such cases displayed raised
serum CEA levels, wherever available.
A. Mucinous adenocarcinoma B. IHC results. Diffuse CK20 positivity and CK 7 negativity (not shown), reinforcing a met-asta ic colorectal adenocarcinomaFigure 2
A. Mucinous adenocarcinoma B. IHC results. Diffuse 
CK20 positivity and CK 7 negativity (not shown), 
reinforcing a metastatic colorectal adenocarcinoma. 
C. Metastatic 'signet-ring' cell adenocarcinoma from colorec-
tum. Infiltrating 'signet-ring' cells in a desmoplastic stroma. 
Inset, showing discrete mucicarmine positivity, highlighting 
intracytoplasmic mucin in the tumor cells. D. CK20 positivity 
in the signet-ring cells. E. Diffuse CEA expression. CK 7 was 
negative (not shown).
Histomorphological patterns in colorectal adenocarcinomasFigure 3
Histomorphological patterns in colorectal adenocar-
cinomas. A. 'Garland-like' necrosis in cases of metastatic 
colorectal adenocarcinomas. B. Intraluminal bridging with 
necrotic debris in cases of endometrioid type of primary 
ovarian adenocarcinoma. C. Conspicuous psammomatous 
calcification in cases of papillary serous cyst adenocarcinomas 
of the ovary. D. Squamous differentiation (arrow) in endome-
trioid adenocarcinoma of the ovary.Page 4 of 7
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were the most valuable clues in diagnosing a metastatic
colorectal carcinoma, as noted in earlier studies [2,5,6].
However, we did not observe stromal luteinization in any
of our cases as noted by Mc Cluggage et al [6] in their
cases. Metastatic mucinous adenocarcinomas can closely
mimic primary ovarian, although, the latter, is invariably
known to display areas resembling borderline primary
ovarian neoplasms. However, this feature can be seen in a
metastatic colorectal adenocarcinoma [11]. Both our cases
of this subtype had histological, as well as gross evidence
of surface involvement, with discrete features of a colonic
adenocarcinoma, including 'garland-like' tumor necrosis.
Presence of lymphovascular emboli favoured a metastatic
carcinoma over a primary. Metastatic colorectal adenocar-
cinomas invariably mimic an endometrioid type of ovar-
ian adenocarcinomas. Identification of foci of squamous
differentiation, endometriosis or adenofibromatosis are
pointers towards an ovarian adenocarcinoma. Despite
these clinicopathological features, difficulty exists,
wherein IHC is valuable in forming a more objective diag-
nosis [6].
Lately, cytokeratins 7 and 20 have been found to be useful
in providing a direction towards exact primary in cases of
metastasis with unknown primary (MUP) [10]. Cytokera-
tin 7 (CK7) is a basic (type II) cytokeratins, found in
human ductal, glandular and transitional epithelia, while
CK 20 it is normally expressed in gastrointestinal epithe-
lium, urothelium and Merkel cells [13,14]. As described
lately, these specific cytokeratins, with additional markers
like CEA and CA125, forming an optimal IHC panel, have
been documented to be helpful in resolving these dilem-
matic situations of ovarian involvement by colorectal car-
cinoma and vice versa. The colonic tumors usually express
CK 20 and CEA diffusely and are negative for CK7 and CA-
125, the latter two being more frequently expressed by
ovarian adenocarcinomas in this clinical context. This pat-
tern of IHC expression helped in ascertaining metastatic
colorectal adenocarcinoma in the ovary in 8/9 cases in our
study. The remaining 1 case was spared with CK 20 expres-
sion since it had identical histomorphological of the
colorectal adenocarcinomas that displayed a transition
from the dysplastic colorectal mucosa. CK7 was focally
positive in 3 such tumors, as noted earlier. [15] Moreover,
CK 20 and CEA positivity can be observed in mucinous
ovarian neoplasms. However, the expression is focal,
unlike diffuse expression noted in lower GI adenocarcino-
mas [6,7,16]. In our limited number of cases in this clini-
cal context, we did not find any pure mucinous ovarian
tumor, although, focal mucinous differentiation was
noted in a single case. Serum CEA levels were marginally
elevated, but IHC for the same was negative. Lately, CDX2
and villin have been found to be 100% positive in cases of
metastatic colorectal adenocarcinomas [11]. However,
CDX2 can be seen in mucinous ovarian adenocarcinoma.
Eleven cases in our series were identified as primary ovar-
ian adenocarcinomas, metastasizing to the colorectum.
A. Primary ovarian adenocarcinoma showing slit-like spaces reminiscent of endom trioid patternFigure 4
A. Primary ovarian adenocarcinoma showing slit-like 
spaces reminiscent of endometrioid pattern. H&E × 
200. B. Focal psammomatous calcification (arrows). H&E × 
200. C. IHC results. Positive CK 7 expression. DAB × 200 D. 
Negative CK20 expression. DAB × 200.
Case of a papillary serouscystadenocarcinoma metastasizing to the sigmoid colonFigure 5
Case of a papillary serouscystadenocarcinoma metas-
tasizing to the sigmoid colon. A. Clusters of tumor cells 
invading the lamina propria and the submucosa. Overlying 
colonic mucosa is normal. H&E × 200. B. Lymphovascular 
emboli in the submucosa. H&E × 400. C. IHC results. CK 7 
highlighting the tumor cells. DAB × 100. Inset showing higher 
magnification of CK7 positive tumor cells. DAB × 200. D. 
Negative CK20. Superficial colonic mucosa showing positivity 
was an internal positive control. DAB × 100.Page 5 of 7
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ovarian tumor. On gross examination, these were
included predominantly in the bilateral ovarian tumors,
with capsular breach and solid and cystic areas. On mor-
phology, metastatic tumor deposits in the colorectum
retained the morphology of ovarian papillary serous cys-
tadeocarcinoma with foci of psammomatous calcification
in 6/11 cases. Absence of 'garland-like' tumor necrosis,
desmoplasia and LVI were pointers towards an ovarian
primary, apart from the clinical context of a preceding
ovarian tumor in 81.8% such cases. Wherever the colonic
resection specimens were available, the tumor was pre-
dominantly submucosal or serosal, with absence of sur-
face dysplasia, ruling out a colonic primary. In view of a
definite clinical diagnosis with identical histomorpholog-
ical features of the primary ovarian adenocarcinoma, IHC
was restricted to 6 out of 11 such cases. In these cases the
IHC pattern included CK7 and CA-125 positivity, with
CEA and CK 20 negativity [16]. Four of these were meta-
chronous (3 treated cases, post CT). Zighelboim et al [3]
described a single case of atypical sigmoid metastasis from
a high-grade ovarian adenocarcinoma, using differential
expression of CK7 & 20. The plausible explanation of
colorectal involvement in ovarian adenocarcinomas is
through intraperitonel seedling. Hematogenous spread
occurs in advanced peritoneal disease. In a substantial
number of autopsy cases of advanced ovarian cancers,
Rose et al [17] identified peritoneal involvement in
83–100% cases, with large intestinal involvement in
50–60% cases. An objective confirmation with specific
cytokeratins in our 6/11 such unusual cases series has not
been described earlier. In most of such cases, serosa was
found to be initially affected and the remaining wall,
thereafter. In their study, O' Hanlan et al [18] hypothe-
sized that ovarian metastases to the gastrointestinal tract
might mimic the colonic pattern of dissemination. In this
setting, the invaded lymph channels at the submucosa of
the bowel enter and replace mesenteric lymph nodes,
forming large deposits of carcinoma in the paracolic and
intermediate mesenteric groups. They concluded that a
longitudinal negative margin of 2 – 5 cm in the resected
bowel along with a wedge resection of mesentery, includ-
ing paracolic and intermediate-level nodes might be indi-
cated to achieve optimal debulking of gastrointestinal
metastases from ovarian carcinomas.
Reardon et al [19] described an ovarian papillary serous
cystadenocarcinoma mimicking recurrence at colorectal
anastomosis in a previously diagnosed case of a colorectal
adenocarcinoma, utilizing progesterone receptor (PR)
expression. The possibility of double cancers in our study
was ruled, based on the aforementioned clinicopatholog-
ical features. Nonetheless there were challenging cases. A
case of an ovarian tumor, on biopsy, showed an adenocar-
cinoma with both, 'garland-like' necrosis and psam-
momatous calcification. Presence of psammomatous
calcification has been rarely documented in colorectal
adenocarcinomas [20]. On IHC, diffuse CK20 and CEA
positivity; with CK7 and CA-125 negativity reinforced a
colonic primary that was further confirmed by presence of
a rectal tumor. Another case presented with a rectal nod-
ule, which was found to be a serosal deposit of a poorly
differentiated adenocarcinoma. Imaging revealed an adn-
exal mass. Histopathologically, unremarkable rectal
mucosa with CK7 positivity and CK 20 negativity in the
tumor cells helped in ruling out a colonic primary. CK 7
is also known to be expressed in breast and the upper
aerodigestive tract [9]. Additionally CA-125 positivity,
along with elevated serum tumor markers levels of CA-
125, confirmed an ovarian origin of the tumor.
Conclusion
In cases of ovarian involvement by colorectal adenocarci-
nomas and vice versa, it can be difficult to ascertain an
exact primary. In such cases, apart from complete clinical
details, histomorphological features like 'garland-like'
necrosis, desmoplasia; presence of lymphovascular
emboli and psammomatous calcification are useful
'pointers' towards exact primary in this scenario. Differen-
tial expression of cytokeratins 7 & 20 by IHC is helpful in
solving these dilemmas. CK7 negativity and CK20 positiv-
ity are indicative of a colonic adenocarcinoma. Addition-
ally, frequent CEA positivity in colorectal tumor vs. CA-
125 expression in ovarian tumors, improves the diagnos-
tic accuracy. Metastatic tumors can present as unilateral
ovarian tumors. More specific markers need to be further
explored and validated with substantial studies to resolve
these diagnostic dilemmas.
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